Focal therapy for localised prostate cancer: Are we asking the correct research questions?

BJU International

Volumn 109, Issue 1, 2012, Pages 1-3

  Murphy, Declan G ^a,b,c   Walton, Thomas J ^c   Connolly, Stephen ^a,c   Costello, Anthony J ^b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Australian Prostate Cancer Research Centre Epworth   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CRYOABLATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SAFETY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

BIOMEDICAL RESEARCH; CATHETER ABLATION; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 83455182012     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10804.x     Document Type: Review

References (12)

1. Heidenreich A, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
2. Hong MK, Namdarian B, Corcoran NM, et al,. Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. Pathology 2011; 43: 138-42
3. Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ,. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int 2011; 108: 1074-85
4. Gburek BM, Kollmorgen TA, Qian J, D'Souza-Gburek SM, Lieber MM, Jenkins RB,. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. J Urol 1997; 157: 223-7 (Pubitemid 26414963)
5. Qian J, Jenkins RB, Bostwick DG,. Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Urology 1995; 46: 837-42
6. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M,. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995; 55: 3346-51
7. Beerlage HP, Thuroff S, Debruyne FM, Chaussy C, de la Rosette JJ,. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology 1999; 54: 273-7 (Pubitemid 29367251)
8. Buxton MJ,. Economic forces and hospital technology. A perspective from Europe. Int J Technol Assess Health Care 1987; 3: 241-51
9. Ahmed HU, Freeman A, Kirkham A, et al,. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011; 185: 1246-54
10. de la Rosette J, Ahmed H, Barentsz J, et al,. Focal therapy in prostate cancer-report from a consensus panel. J Endourol 2010; 24: 775-80
11. Murphy DG, Pedersen J, Costello AJ,. Salvage robotic-assisted laparoscopic radical prostatectomy following failed primary high-intensity focussed ultrasound treatment for localised prostate cancer. J Robotic Surg 2008; 2: 201-3
12. Lawrentschuk N, Finelli A, Van der Kwast TH, et al,. Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. J Urol 2011; 185: 862-8